SVCC
Strong SellSinkerStellar V Capital Corp. · Financial Services · United States · $232M cap · $2.0M/day traded
$10.66 -0.4% · close 4 Nov · scored 5 Nov
StockRank down 2.1 since 4 Nov: Momentum down 3.
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 5 Nov 2026, MoatMap's StockRank for Stellar V Capital Corp. (SVCC) is 19/100, ranked against 24,000+ stocks in 35 markets (Quality 32, Value 21, Momentum 47, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
ABOUT STELLAR V CAPITAL CORP.
Read
Stellar V Capital Corp. is a special purpose acquisition company (SPAC) established to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. As a shell company with no ongoing operations, its value is derived from the experience of its management team in identifying and completing a compelling acquisition target. The success of SVCC hinges on its ability to find an attractive private company to bring public.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | 0 | 0 | — |
| EPS | -0.01 | 0.26 | 0.22 |
| Shares | 21.6M | 21.6M | 21.6M |
| Debt | 0.2M | — | 50.0K |
| Equity | -50.8K | 151.8M | — |
| Op CF | 0 | -0.6M | -0.5M |
| Inv CF | 0 | -151.1M | — |
| Fin CF | 0 | 152.0M | — |
Above its 200-day average and 7% below its 52-week high.
The Momentum score still reads 47: it weighs six months of price and earnings revisions, so it trails a turn like this.
Calmer than 100% of stocks we rank over the past year (volatility 4% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of SVCC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SVCC | Stellar V Capital Corp.(you) | $232M | 19 | Strong Sell |
| EGHA | EGH Acquisition Corp. | $214M | 18 | Strong Sell |
| BLRK | Bluerock Acquisition Corp. | $232M | 15 | Strong Sell |
| NTWO | Newbury Street II Acquisition Corp | $261M | 18 | Strong Sell |
| DMAA | Drugs Made In America Acquisition Corp. | $264M | 20 | Strong Sell |
| DYNC | Dynamix Corporation | $242M | 15 | Strong Sell |
| TWLV | Twelve Seas Investment Company III | $236M | 23 | Sell |
| OACC | Oaktree Acquisition Corp. III Life Sciences | $263M | 21 | Sell |
| IGAC | Invest Green Acquisition Corporation | $242M | 23 | Sell |
| MCGA | Yorkville Acquisition Corp. | $245M | 23 | Sell |
Peer medians: ROE 9.6% · P/E 13.0x · Gross margin 73.0%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.